South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - solution - see ingredients - each 1,0 ml solution contains lamivudine 10,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - syrup - see ingredients - each 5,0 ml syrup contains zidovudine 50,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - syrup - see ingredients - each 5,0 ml syrup contains zidovudine 50,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - solution - see ingredients - each 2,5 ml contains ipratropium bromide 0,520 mg salbutamol sulphate 3,010 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - injection - see ingredients - each 15,0 ml solution contains pantoprazole 40,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; triacetin; microcrystalline cellulose; sodium lauryl sulfate; titanium dioxide; hyprolose; iron oxide yellow; iron oxide red; purified talc; magnesium stearate; hypromellose - adcirca is indicated in adults for the treatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - powder for concentrate for solution for infusion - enfortumab vedotin 20 mg/vial - enfortumab vedotin - padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (muc) who: - have previously received a programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd-l1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or:- are ineligible for cisplatin-containing chemotherapy and have previously received a pd-1/pd-l1 inhibitor.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - powder for concentrate for solution for infusion - enfortumab vedotin 30 mg/vial - enfortumab vedotin - padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (muc) who: - have previously received a programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd-l1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or:- are ineligible for cisplatin-containing chemotherapy and have previously received a pd-1/pd-l1 inhibitor.

Israel - English - Ministry of Health

takeda israel ltd - brentuximab vedotin - powder for concentrate for solution for infusion - brentuximab vedotin 50 mg/vial - brentuximab vedotin - adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl): 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following asct. adcetris is indicated for the treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy . adcetris is indicated for the treatment of adult patients with previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine.adcetris is indicated for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

European Union - English - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastic agents - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.